HSP90α与HSP90β协同促进肺纤维化中肌成纤维细胞持续存在
该研究探讨热休克蛋白HSP90α和HSP90β在肺纤维化中的作用。研究发现IPF患者循环HSP90α升高且与疾病严重程度相关,机械应力促进其释放,胞外HSP90α经LRP1促进肌成纤维细胞分化与持续存在,而胞内HSP90β稳定LRP1放大该效应。
要点
- IPF患者循环HSP90α升高并与疾病严重程度相关
- 胞外HSP90α经LRP1促进肌成纤维细胞分化与持续存在
- 特异性抑制胞外HSP90α可能是减少促纤维化信号的潜在策略
核心结论
- HSP90α与HSP90β协同促进肺纤维化中肌成纤维细胞持续存在,特异性抑制胞外HSP90α是IPF的潜在治疗策略。
研究设计与样本
- 研究检测了IPF患者(n=31)与年龄匹配健康对照(n=9)的循环HSP90α水平,并在原代IPF与对照肺成纤维细胞及接受腺病毒载体介导TGF-β1的大鼠纤维化肺切片机械牵张后评估HSP90α与HSP90β释放。
主要发现
- IPF患者循环HSP90α上调,且与疾病严重程度相关。
- 纤维化ECM机械应力增加可增强HSP90α释放。
- 胞外HSP90α经LRP1信号促进肌成纤维细胞分化与持续存在。
- 胞内HSP90β稳定LRP1,从而放大HSP90α的胞外作用。
临床怎么用
- 提示胞外HSP90α-LRP1轴可作为IPF抗纤维化治疗的潜在干预靶点,但尚需进一步临床验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Idiopathic pulmonary fibrosis (IPF) is a progressive disease of the lung parenchyma, causing significant morbidity through worsening dyspnoea and overall functional decline. IPF is characterised by apoptosis-resistant myofibroblasts, which are a major source for the excessive production of extracellular matrix (ECM) overtaking normal lung tissue. We sought to study the role of heat shock protein (HSP) isoforms HSP90α and HSP90β, whose distinct roles in lung fibrogenesis remain elusive.We determined the level of circulating HSP90α in IPF patients (n=31) and age-matched healthy controls (n=9) by ELISA. The release of HSP90α and HSP90β was evaluated in vitro in primary IPF and control lung fibroblasts and ex vivo after mechanical stretch on fibrotic lung slices from rats receiving adenovector-mediated transforming growth factor-β1.We demonstrate that circulating HSP90α is upregulated in IPF patients in correlation with disease severity. The release of HSP90α is enhanced by the increase in mechanical stress of the fibrotic ECM. This increase in extracellular HSP90α signals through low-density lipoprotein receptor-related protein 1 (LRP1) to promote myofibroblast differentiation and persistence. In parallel, we demonstrate that the intracellular form of HSP90β stabilises LRP1, thus amplifying HSP90α extracellular action.We believe that the specific inhibition of extracellular HSP90α is a promising therapeutic strategy to reduce pro-fibrotic signalling in IPF.
引用
- Bellaye PS, Shimbori C, Yanagihara T, et al. Synergistic role of HSP90α and HSP90β to promote myofibroblast persistence in lung fibrosis. Eur Respir J. 2018. PMID: 29386344. doi:10.1183/13993003.00386-2017
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。